Evidence map›Paper›PMID 38611809›Full record

ArticleMolecules (Basel, Switzerland)2024

Chlorpromazine-Polypyrrole Drug Delivery System Tailored for Neurological Application.

Sara Krawczyk, Sylwia Golba, Cristina Neves, João Tedim

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Sara KrawczykDepartment of Science and Technology, Institute of Materials Engineering, Doctoral School, University of Silesia, Bankowa 14, 40-007 Katowice, Poland.ORCID 0000-0001-9306-7738
Sylwia GolbaDepartment of Science and Technology, Institute of Materials Engineering, Bankowa 14, 40-007 Katowice, Poland.ORCID 0000-0003-4550-0490
Cristina NevesDepartment of Materials and Ceramic Engineering, Centre for Research in Ceramics and Composite Materials (CICECO), University of Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal.ORCID 0000-0002-9530-6963
João TedimDepartment of Materials and Ceramic Engineering, Centre for Research in Ceramics and Composite Materials (CICECO), University of Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal.ORCID 0000-0002-7584-4641
University of Aveiro · PTUniversity of Silesia in Katowice · PL

Funding

CICECO-Aveiro Institute of Materials FCT/MCTES (PIDDAC). UIDB/50011/2020, UIDP/50011/2020 & LA/P/0006/2020Research Excellence Initiative of the University of Silesia in Katowice and Doctoral School Financial Source. ZFIN 00001022 (IDB)
6 · The paper itself

Abstract

Nowadays, drug delivery systems (DDSs) are gaining more and more attention. Conducting polymers (CPs) are efficiently used for DDS construction as such systems can be used in therapy. In this research, a well-known CP, polypyrrole (PPy), was synthesized in the presence of the polysaccharide heparin (HEP) and chlorpromazine (CPZ) using sodium dodecyl sulfate (SDS) as electrolyte on a steel substrate. The obtained results demonstrate the successful incorporation of CPZ and HEP into the polymer matrix, with the deposited films maintaining stable electrochemical parameters across multiple doping/dedoping cycles. Surface roughness, estimated via AFM analysis, revealed a correlation with layer thickness-decreasing for thinner layers and increasing for thicker ones. Moreover, SEM images revealed a change in the morphology of PPy films when PPy is electropolymerized in the presence of CPZ and HEP, while FTIR confirmed the presence of CPZ and HEP within PPy. Due to its lower molecular mass compared to HEP, CPZ was readily integrated into the thin polymer matrix during deposition, with diffusion being unimpeded, as opposed to films with greater thickness. Finally, the resulting system exhibited the ability to release CPZ, enabling a dosing range of 10 mg to 20 mg per day, effectively covering the therapeutic concentration range.

Indexed as

ChlorpromazinePolymersDrug Delivery SystemsHeparinPyrrolesChlorpromazineHeparinPolymerspolypyrrolePyrrolesconducting polymersdrug delivery systemheparinphenothiazine derivativespolypyrrole

Identifiers

PMID38611809
PMCPMC11013625
OpenAlexW4393309711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.